Dr. McLain is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2229 Cahaba Valley DR
Birmingham, AL 35242Phone+1 205-991-8996Fax+1 205-991-8997
Summary
- David McLain, a Birmingham, AL-based Rheumatologist, earned his MD from Tulane U. and completed his residency/fellowship at Wash. U./Barnes. He is Symposium Dir. for the Congress of Clinical Rheumatology, Exec. Dir. of the AL Soc. for Rheumatic Dis. , and at McLain Med Assoc. He has research work on low-dose naltrexone for chronic pain. Dr. McLain is a Fellow of the Royal Coll. of Physicians.
Clinical Expertise
- Principal Investigator, Rheumatoid arthritis, Systemic lupus erythematosus, Sjogren's syndrome, Psoriatic arthritis, Gout, Fibromyalgia, Hashimoto's thyroiditis, Ankylosing spondylitis, Osteoporosis, Osteoarthritis, Reactive arthritis, Systemic Scleroderma, Arthritis, Submersion injury
Education & Training
- International Society for Clinical DensitometryC.C.D, Clinical, Densitometry, 2002 - 2002
- Washington University/B-JH/SLCH ConsortiumFellowship, Rheumatology, 1977 - 1979
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1975 - 1977
- Ochsner Clinic FoundationInternship, Internal Medicine, 1974 - 1975
- Tulane University School of MedicineClass of 1974
- Northwestern UniversityBA, Psychology, Premed, 1966 - 1970
Certifications & Licensure
- AL State Medical License 1981 - 2025
- LA State Medical License 1974 - 1977
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow Royal College of Physicians (London, England), 2023
- Master (MACR) American College of Rheumatology
- Patients’ Choice Award winner vitals.com, 2011-2018
- Join now to see all
Clinical Trials
- Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee Start of enrollment: 2006 Mar 01
Publications & Presentations
PubMed
- 3 citationsMissing the Mark? American College of Rheumatology 2019 Guidelines for Intraarticular Hyaluronic Acid Injection and Osteoarthritis Knee Pain.Roy D Altman, Robert W Ike, Max I Hamburger, David A McLain, Michael J Daley
The Journal of Rheumatology. 2022-08-01 - 149 citationsThe use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic painJarred Younger, Luke Parkitny, David A. McLain
Clinical Rheumatology. 2014-02-15 - 4 citationsCost analysis of flavocoxid compared to naproxen for management of mild to moderate OASurrey M. Walton, Glen T. Schumock, David A. McLain
Current Medical Research and Opinion. 2010-08-15
Journal Articles
- The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic painJarred Younger, Luke Parkitny, David McLain, Clinical Rheumatology, 2/2014
- Medicine does not exist in a Vacuum.McLain, DA, MASA Review, 1: 23-25
- Current trends in the Diagnosis and Treatment of Chronic Neuromuscular Pain Syndromes: Myofascial Pain Syndrome, Chronic Tension-Type Headache, and Fibromyalgia.Jay, GW, Krusz, JC, Longmire, DR, McLain, DA, The American Academy of Pain Management
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Colchicine and PseudogoutMcLain, DA, Spilberg, l, Berney, S. Simchowitz, L, Arthritis and Rheumatism, 23: 718
- An HLA Public Antigen is More Common than HLA B27 in Patients with Ankylosing Spondylitis.McLain, DA, Luehrman, LK, Rodey, GE, Schwartz, BD, Arthritis and Rheumatism, 23: 718
- HLA Public Antigen is More Common than HLA B27 in Patients with Ankylosing Spondylitisn, in Preud'Homme and Hawken.McLain, DA, Luehrman, LK, Rodey, GE, Schwartz, BD, 4th International Congress of Immunology, Paris
- Join now to see all
Authored Content
- A Vast Array of Eye-Opening Studies Were Featured at ACR 2022November 2022
- Commentary on Manzi Lupus articleJuly 2019
- Commentary on Filgotinib in RA articleJuly 2019
- Commentary on EULAR Gout guidelinesJuly 2019
- Commentary on Ankylosing Spondylitis and use of OpioidsJune 2019
- Commentary on Stem Cell ClinicsJune 2019
- Commentary on Steroid use in GCA and PMR and infection riskJune 2019
- Commentary on Barriers to control of RAJune 2019
- Commentary on when to stop medications in unplanned pregnanciesJune 2019
- Join now to see all
Press Mentions
- Quick Facts About Fibromyalgia and Related DiseasesJanuary 14th, 2017
Research History
- Principal Investigator, Achieve Clinical Research, LLC--rheumatoid arthritis, osteoporosis, osteoarthritis, lupus, psoriatic arthritis, fibromyalgia2008 - 2014
Professional Memberships
- Fellow
- United RheumatologyMember
- Member
- Alabama Society for the Rheumatic Diseases (ASRD)Executive Director
- Member
- Medical Association of the States of Alabama (MASA)Member
- Jefferson County Medical SocietyMember
- Royal College of Physicians, LondonFellow
External Links
- Fibromyalgia Updatehttps://www.youtube.com/watch?v=7XSqUBiil-k&feature=youtu.be
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: